Confronting the Challenges of Atrial Fibrillation

Login or register to view PDF.
Citation
US Cardiology, 2006;3(2):103-7

Pages

Atrial fibrillation (AF) is the most frequent serious arrhythmia encountered in clinical practice. It is usually symptomatic; can reduce quality of life; commonly results in hospitalization; typically requires multiple drugs in its treatment; and can result in heart failure, embolization and its consequences, and death. Even when AF itself does not directly provoke symptoms leading to its awareness by the patient, it may still result in tachycardia-induced cardiomyopathy, embolic phenomena, and mortality.This 'silentÔÇÖ or 'asymptomaticÔÇÖ AF occasionally exists in the absence of symptomatic AF (<20% of AF patients) or may coexist with alternate periods of symptomatic AF (up to 70% of AF patients).1,2 Generally, but not consistently, periods of asymptomatic AF have slower ventricular rates than symptomatic periods, whether spontaneously or via rate-control agents).Asymptomatic AF also appears to occur relatively frequently following ablative procedures targeting the elimination of AF, speculatively due to incomplete success but alteration of sensory nerve signals.

Therapeutically, the management of AF is a challenge to even the most sophisticated practitioner, and confronting the challenges of AF can be difficult at best to exhausting on occasion. Such challenges revolve around issues of:

  • rate control versus rhythm control as the primary management approach in the patient at hand;
  • methods of rate control and/or rhythm control;
  • definitions of therapeutic success;
  • anticoagulation; and
  • the use of 'ancillaryÔÇÖ pharmacologic agents.

In an attempt to confront these challenges, perhaps we would do best to address them one by one.

Rate Controlversus Rhythm Control

Most clinicians are likely now aware that in the past half-decade or so, multiple clinical trials have been performed in a variety of AF populations to assess whether the pursuit and attainment of sinus rhythm affords a benefit to the AF patient in contrast to the benefits attained using a strategy of rate control as the primary management goal. These trials included the small Pharmacological Intervention in Atrial Fibrillation (PIAF), Strategies of Treatment of Atrial Fibrillation (STAF), and How to Treat Chronic Atrial Fibrillation (HOT-CAFÉ) studies, the intermediate-sized A Comparison of Rate Control and Rhythm Control in Patients With Recurrent Persistent Atrial Fibrillation (RACE) trial, and the large Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial.3-7

Pages

References
  1. Fetsch T, Bauer P, Engberding R, et al., "Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial", Eur Heart J (2004);25: pp. 1385-1394.
    Crossref | PubMed
  2. Israel CW, Gronefeld G, Ehrlich R, et al., "Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care", J Am Coll Cardiol (2004);43: pp. 47-52.
    Crossref | PubMed
  3. Hohnloser SH, Kuck K, Lilienthal J, "Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial fibrillation (PIAF): a randomized trial", Lancet (2000);356: pp. 1789-1794.
    Crossref | PubMed
  4. Carlsson J, Miketic S,Windeler J, et al.,"Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial fibrillation (STAF) study", J Am Coll Cardiol (2003);41: pp. 1690-1696.
    Crossref | PubMed
  5. Opolski G,Torbicki A, Kosior DA, et al., "Rate control versus rhythm control in patients with nonvalvular persistent atrial fibrillation : the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study", Chest (2004);126: pp. 476-486.
    Crossref | PubMed
  6. Van Gelder IC, Hagens VE, Bosker HA, et al., "A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation", N Engl J Med (2002);347: pp. 1834-1840.
    Crossref | PubMed
  7. The AFFIRM Investigators,"A comparison of rate control and rhythm control in patients with atrial fibrillation", N Engl J Med (2002);347: pp. 1825-1833.
    Crossref | PubMed
  8. The AFFIRM Investigators, "Relationships between sinus rhythm, treatment, and survival in the Atrial fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study", Circulation (2004);109: pp. 1509-1513.
    Crossref | PubMed
  9. Blitzer M, Costeas C, Kassotis J, et al.,"Rhythm management in atrial fibrillation with a primary emphasis on pharmacologic therapy - part 1", PACE (1998);21: pp. 590-602.
    Crossref | PubMed
  10. Fuster V, Ryden LE, Asinger RW, et al.,"ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary", Circulation (2001);104: pp. 2118-2150.
    PubMed
  11. Fuster V, Ryden LE, Cannon DS, et al., "ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary", Circulation (2006);114: pp. 700-752.
    Crossref
  12. Reiffel JA, Naccarelli GV, "Antiarrhythmic drug therapy for atrial fibrillation: are the guidelines guiding clinical practice?", Clin Cardiol (2006);29: pp. 97-102.
    Crossref | PubMed
  13. Reiffel JA,"Have sanctioned algorithms replaced empiric judgment in the selection processs of antiarrhythmic drugs for the therapy for atrial fibrillation?", Current Cardiol Reports (2004);6: pp. 365-370.
    Crossref | PubMed
  14. Costeas C, Kassotis J, Blitzer M, et al.,"Rhythm management in atrial fibrillationÔÇöwith a primary emphasis on pharmacological therapy: Part 2," PACE (1998);21: pp. 742-752.
    Crossref | PubMed
  15. Go AS, Hylek EM, Borowsky LH, et al., "Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study", Ann Intern Med (1999);131: pp. 927-934.
    Crossref | PubMed
  16. Waldo AL, Becker RC,Tapson VT, et al., "Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation", J Am Coll Cardiol (2005);46: pp. 1729-1736.
    Crossref | PubMed
  17. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators, "Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomised controlled trial", Lancet (2003);362: pp. 1691-1698.
    Crossref | PubMed
  18. Diener HC, Executive Steering Committee on behalf of the SPORTIF III and V Investigators,"Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies", Cerebrovas Dis (2006);21(4): pp. 279-293.
    Crossref | PubMed
  19. Reiffel JA,"Formulation substitution: a frequently overlooked variable in cardiovascular drug management", Prog in Cardiovasc Diseases (2004);47: pp. 3-10.
    Crossref | PubMed
  20. Piorkowski C, Kottkamp H,Tanner H, et al., "Value of different follow-up strategies to assess the efficacy of circumferential pulmonary vein ablation for the curative treatment of atrial fibrillation", J Cardiovasc Electrophysiol (2005);16: pp. 1286-1292.
    Crossref | PubMed
  21. Healey JS, Morillo CA, Connolly SJ, "Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling", Current Opinion in Cardiology (2005);20: pp. 31-37.
    PubMed
  22. Anand K, Mooss AN, Hee TT, et al., "Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation", A Heart J (2006);152: pp. 217-222.
    Crossref | PubMed
  23. Murray KT, Rottman JN, Arbogast PG, et al., "Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM", Heart Rhythm (2004);1: pp. 669-675.
    Crossref | PubMed
  24. Young-Xu Y, Jabbour S, Goldberg R, et al., "Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease", Am J Cardiol (2003);92: pp. 1379-1383.
    Crossref | PubMed
  25. Lozano HF, Conde CA, Florin T, et al.,"Treatment and prevention of atrial fibrillation with non-antiarrhythmic pharmacologic therapy", Heart Rhythm (2005);2: pp. 1000-1007.
    Crossref | PubMed
  26. Marin F, Pascual DA, Roldan V, et al., "Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting", Am J Cardiol (2006);97: pp. 55-60.
    Crossref | PubMed
  27. Siu CW, Lau CP,Tse HF,"Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion", Am J Cardiol (2003);92: pp. 1343-1345.
    Crossref | PubMed
  28. Calo L, Bianconi L, Colivicchi F, et al., "N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial", J Am Coll Cardiol (2005);45: pp. 1723-1728.
    Crossref | PubMed
  29. Biscione F,Totteri A, De Vita A, et al., "Effect of omega-3 fatty acids on the prevention of atrial arrhythmias", Italian Heart Journal (2005);6(suppl): pp. 53-59.
    PubMed
  30. Patti G, Chello M, Candura D, et al.,"Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study", Circulation (2006);114: pp. 1455-1461.
    Crossref | PubMed
  31. Reiffel JA, McDonald A,"Antiarrhythmic effects of omega-3 fatty acids", Am J Cardiol (2006);98(4A): pp. 50i-60i.
    Crossref | PubMed
  32. Aviles RJ, Martin DO, Apperson-Hansen C, et al., "Inflammation as a risk factor for atrial fibrillation", Circulation (2003); 108: pp. 3006-3010.
    Crossref | PubMed
  33. Hatzinikolaou-Kotsakou E,Tziakas D, Hotidis A, et al.,"Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation", Am J Cardiol (2006);9: pp. 659-661.
    Crossref | PubMed
  34. Coumel P, "Neural aspects of paroxysmal atrial fibrillation", in: Falk RH, Podrid PJ (eds), Atrial Fibrillation: Mechanisms and Management, New York: Raven Press (1992): pp. 109-125.
  35. Madrid AH, Bueno MG, Rebollo JM, et al.,"Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study", Circulation (2002);10: pp. 331-336.
    Crossref | PubMed
  36. Ueng KC,Tsai TP,Yu WC, et al., "Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of longstanding persistent atrial fibrillation. Results of a prospective and controlled study", Eur Heart J (2003);24: pp. 2090-2098.
    Crossref | PubMed